Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer

Dong Wook Kim, Weon Kuu Chung, Dongoh Shin, Seongeon Hong, Sung Ho Park, Sung Yong Park, Kwangzoo Chung, Young Kyung Lim, Dongho Shin, Se Byeong Lee, Hyun ho Lee, Myonggeun Yoon

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: To compare the risk of secondary cancer from scattered and leakage doses following intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT) and tomotherapy (TOMO) in patients with lung cancer. Methods: IMRT, VMAT and TOMO were planned for five lung cancer patients. Organ equivalent doses (OEDs) are estimated from the measured corresponding secondary doses during irradiation at various points 20 to 80 cm from the iso-center by using radio-photoluminescence glass dosimeter (RPLGD). Results: The secondary dose per Gy from IMRT, VMAT and TOMO for lung cancer, measured 20 to 80 cm from the iso-center, are 0.02~2.03, 0.03~1.35 and 0.04~0.46 cGy, respectively. The mean values of relative OED of secondary dose of VMAT and TOMO, which is normalized by IMRT, ranged between 88.63% and 41.59% revealing 88.63% and 41.59% for thyroid, 82.33% and 41.85% for pancreas, 77.97% and 49.41% for bowel, 73.42% and 72.55% for rectum, 74.16% and 81.51% for prostate. The secondary dose and OED from TOMO became similar to those from IMRT and VMAT as the distance from the field edge increased. Conclusions: OED based estimation suggests that the secondary cancer risk from TOMO is less than or comparable to the risks from conventional IMRT and VMAT.

Original languageEnglish
Article number47
JournalRadiation Oncology
Volume8
Issue number1
DOIs
Publication statusPublished - 2013 Mar 4

Fingerprint

Intensity-Modulated Radiotherapy
Second Primary Neoplasms
Lung Neoplasms
Radiation
Therapeutics
Radio
Rectum
Glass
Prostate
Pancreas
Neoplasms
Thyroid Gland

Keywords

  • IMRT
  • OED
  • Radio-photoluminescence
  • Secondary dose
  • TOMOTHERAPY
  • VMAT

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer. / Kim, Dong Wook; Chung, Weon Kuu; Shin, Dongoh; Hong, Seongeon; Park, Sung Ho; Park, Sung Yong; Chung, Kwangzoo; Lim, Young Kyung; Shin, Dongho; Lee, Se Byeong; Lee, Hyun ho; Yoon, Myonggeun.

In: Radiation Oncology, Vol. 8, No. 1, 47, 04.03.2013.

Research output: Contribution to journalArticle

Kim, DW, Chung, WK, Shin, D, Hong, S, Park, SH, Park, SY, Chung, K, Lim, YK, Shin, D, Lee, SB, Lee, HH & Yoon, M 2013, 'Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer', Radiation Oncology, vol. 8, no. 1, 47. https://doi.org/10.1186/1748-717X-8-47
Kim, Dong Wook ; Chung, Weon Kuu ; Shin, Dongoh ; Hong, Seongeon ; Park, Sung Ho ; Park, Sung Yong ; Chung, Kwangzoo ; Lim, Young Kyung ; Shin, Dongho ; Lee, Se Byeong ; Lee, Hyun ho ; Yoon, Myonggeun. / Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer. In: Radiation Oncology. 2013 ; Vol. 8, No. 1.
@article{6329d4c179e5491da467309d3311025c,
title = "Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer",
abstract = "Purpose: To compare the risk of secondary cancer from scattered and leakage doses following intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT) and tomotherapy (TOMO) in patients with lung cancer. Methods: IMRT, VMAT and TOMO were planned for five lung cancer patients. Organ equivalent doses (OEDs) are estimated from the measured corresponding secondary doses during irradiation at various points 20 to 80 cm from the iso-center by using radio-photoluminescence glass dosimeter (RPLGD). Results: The secondary dose per Gy from IMRT, VMAT and TOMO for lung cancer, measured 20 to 80 cm from the iso-center, are 0.02~2.03, 0.03~1.35 and 0.04~0.46 cGy, respectively. The mean values of relative OED of secondary dose of VMAT and TOMO, which is normalized by IMRT, ranged between 88.63{\%} and 41.59{\%} revealing 88.63{\%} and 41.59{\%} for thyroid, 82.33{\%} and 41.85{\%} for pancreas, 77.97{\%} and 49.41{\%} for bowel, 73.42{\%} and 72.55{\%} for rectum, 74.16{\%} and 81.51{\%} for prostate. The secondary dose and OED from TOMO became similar to those from IMRT and VMAT as the distance from the field edge increased. Conclusions: OED based estimation suggests that the secondary cancer risk from TOMO is less than or comparable to the risks from conventional IMRT and VMAT.",
keywords = "IMRT, OED, Radio-photoluminescence, Secondary dose, TOMOTHERAPY, VMAT",
author = "Kim, {Dong Wook} and Chung, {Weon Kuu} and Dongoh Shin and Seongeon Hong and Park, {Sung Ho} and Park, {Sung Yong} and Kwangzoo Chung and Lim, {Young Kyung} and Dongho Shin and Lee, {Se Byeong} and Lee, {Hyun ho} and Myonggeun Yoon",
year = "2013",
month = "3",
day = "4",
doi = "10.1186/1748-717X-8-47",
language = "English",
volume = "8",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer

AU - Kim, Dong Wook

AU - Chung, Weon Kuu

AU - Shin, Dongoh

AU - Hong, Seongeon

AU - Park, Sung Ho

AU - Park, Sung Yong

AU - Chung, Kwangzoo

AU - Lim, Young Kyung

AU - Shin, Dongho

AU - Lee, Se Byeong

AU - Lee, Hyun ho

AU - Yoon, Myonggeun

PY - 2013/3/4

Y1 - 2013/3/4

N2 - Purpose: To compare the risk of secondary cancer from scattered and leakage doses following intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT) and tomotherapy (TOMO) in patients with lung cancer. Methods: IMRT, VMAT and TOMO were planned for five lung cancer patients. Organ equivalent doses (OEDs) are estimated from the measured corresponding secondary doses during irradiation at various points 20 to 80 cm from the iso-center by using radio-photoluminescence glass dosimeter (RPLGD). Results: The secondary dose per Gy from IMRT, VMAT and TOMO for lung cancer, measured 20 to 80 cm from the iso-center, are 0.02~2.03, 0.03~1.35 and 0.04~0.46 cGy, respectively. The mean values of relative OED of secondary dose of VMAT and TOMO, which is normalized by IMRT, ranged between 88.63% and 41.59% revealing 88.63% and 41.59% for thyroid, 82.33% and 41.85% for pancreas, 77.97% and 49.41% for bowel, 73.42% and 72.55% for rectum, 74.16% and 81.51% for prostate. The secondary dose and OED from TOMO became similar to those from IMRT and VMAT as the distance from the field edge increased. Conclusions: OED based estimation suggests that the secondary cancer risk from TOMO is less than or comparable to the risks from conventional IMRT and VMAT.

AB - Purpose: To compare the risk of secondary cancer from scattered and leakage doses following intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT) and tomotherapy (TOMO) in patients with lung cancer. Methods: IMRT, VMAT and TOMO were planned for five lung cancer patients. Organ equivalent doses (OEDs) are estimated from the measured corresponding secondary doses during irradiation at various points 20 to 80 cm from the iso-center by using radio-photoluminescence glass dosimeter (RPLGD). Results: The secondary dose per Gy from IMRT, VMAT and TOMO for lung cancer, measured 20 to 80 cm from the iso-center, are 0.02~2.03, 0.03~1.35 and 0.04~0.46 cGy, respectively. The mean values of relative OED of secondary dose of VMAT and TOMO, which is normalized by IMRT, ranged between 88.63% and 41.59% revealing 88.63% and 41.59% for thyroid, 82.33% and 41.85% for pancreas, 77.97% and 49.41% for bowel, 73.42% and 72.55% for rectum, 74.16% and 81.51% for prostate. The secondary dose and OED from TOMO became similar to those from IMRT and VMAT as the distance from the field edge increased. Conclusions: OED based estimation suggests that the secondary cancer risk from TOMO is less than or comparable to the risks from conventional IMRT and VMAT.

KW - IMRT

KW - OED

KW - Radio-photoluminescence

KW - Secondary dose

KW - TOMOTHERAPY

KW - VMAT

UR - http://www.scopus.com/inward/record.url?scp=84874400422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874400422&partnerID=8YFLogxK

U2 - 10.1186/1748-717X-8-47

DO - 10.1186/1748-717X-8-47

M3 - Article

C2 - 23452670

AN - SCOPUS:84874400422

VL - 8

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 47

ER -